# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating.
HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price targ...
Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of ...
Piper Sandler analyst Joseph Catanzaro initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating and a...
Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas o...
B. Riley Securities analyst Yuan Zhi initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Buy rating and announces ...